Is REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 43.9% / 30% | 1291.5% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 43.9% / 33% | 1291.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 3.0% / 33% | 86.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 43.9% / 33% | 1291.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 3.0% / 33% | 86.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -130.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$34M |
| Free Cash Flow | -$34M |
| Total Debt | $458,154 |
| Current Ratio | 1.4 |
| Total Assets | $16M |
Price & Trading
| Last Close | $0.78 |
| 50-Day MA | $4.31 |
| 200-Day MA | $8.52 |
| Avg Volume | 414K |
| Beta | 0.2 |
|
52-Week Range
$0.67
| |
About REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), REVIVA PHARMACEUTICALS HOLDINGS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is REVIVA PHARMACEUTICALS HOLDINGS, INC.'s debt ratio?
REVIVA PHARMACEUTICALS HOLDINGS, INC.'s debt ratio is 43.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.0%.
What are REVIVA PHARMACEUTICALS HOLDINGS, INC.'s key financial metrics?
REVIVA PHARMACEUTICALS HOLDINGS, INC. has a market capitalization of $9M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.